BlossomHill Therapeutics, Inc.: Cui Jingrong Jean discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cui Jingrong Jean disclosed a stake of more than 5% in BlossomHill Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001193125-26-464174). The filing signals a significant ownership position in the clinical-stage oncology company by the insider. The exact share count and percentage above the 5% threshold were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
BlossomHill Therapeutics, Inc., Cui Jingrong Jean